Arrowhead’s gene silencer competitive with Ionis’ in triglyceride disease

July 22, 2026 11:32 AM EDT R&DPharma Ar­row­head’s gene si­lencer com­pet­i­tive with Io­n­is’ in triglyc­eride dis­ease Elizabeth Cairns Senior biopharma journalist Ar­row­head Phar­ma­ceu­ti­cals’ lipid-low­er­ing drug has hit in two late-stage tri­als that could ex­pand its use in­to a much wider pop­u­la­tion. Da­ta Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER